about
Measles immunity and response to revaccination among secondary school children in CumbriaUse of Vaxfectin adjuvant with DNA vaccine encoding the measles virus hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques against measles virusChikungunya vaccines in developmentA Blueprint for HIV Vaccine DiscoveryVaccine-mediated immunity against dengue and the potential for long-term protection against diseaseSang Froid in a time of trouble: is a vaccine against HIV possible?The Immune Response in Measles: Virus Control, Clearance and Protective ImmunityHigh antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus modelComparison of the immune responses induced by chimeric alphavirus-vectored and formalin-inactivated alum-precipitated measles vaccines in miceImmunology of Gut Mucosal VaccinesNeutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model.Standardization of measles, mumps and rubella assays to enable comparisons of seroprevalence data across 21 European countries and Australia.Immunosorbent assay based on recombinant hemagglutinin protein produced in a high-efficiency mammalian expression system for surveillance of measles immunity.Development of replication-competent viral vectors for HIV vaccine delivery.Waning of maternal antibodies against measles, mumps, rubella, and varicella in communities with contrasting vaccination coverage.A chimeric alphavirus replicon particle vaccine expressing the hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques from measlesSuccessful vaccine-induced seroconversion by single-dose immunization in the presence of measles virus-specific maternal antibodiesHuman parainfluenza virus type 3 (PIV3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PIV3 in early infancy.Antibody levels to tetanus, diphtheria, measles and varicella in patients with primary immunodeficiency undergoing intravenous immunoglobulin therapy: a prospective study.A chimeric human-bovine parainfluenza virus type 3 expressing measles virus hemagglutinin is attenuated for replication but is still immunogenic in rhesus monkeys.Characterization of immune responses induced by intramuscular vaccination with DNA vaccines encoding measles virus hemagglutinin and/or fusion proteins.Modulation of disease, T cell responses, and measles virus clearance in monkeys vaccinated with H-encoding alphavirus replicon particles.Relative contributions of measles virus hemagglutinin- and fusion protein-specific serum antibodies to virus neutralizationHIV-1 infection in Zambian children impairs the development and avidity maturation of measles virus-specific immunoglobulin G after vaccination and infection.Measles seropositivity in HIV-infected Kenyan children on antiretroviral therapy.Estimating vaccination coverage for the trivalent measles-mumps-rubella vaccine from trivariate serological data.Successful boosting of a DNA measles immunization with an oral plant-derived measles virus vaccineVariability in immune response to pathogens: using measles vaccine to probe immunogenetic determinants of responseInfluence of maternal antibodies on neonatal immunization against respiratory viruses.Transplacental transfer of macromolecules: proving the efficiency of placental transfer of maternal measles antibodies in mother: infant pairsEvaluation of a two-dose measles, mumps, and rubella vaccination schedule in a cohort of college athletesMeasles control in developing and developed countries: the case for a two-dose policy.Long-term safety and serologic response to measles, mumps, and rubella vaccination in HIV-1 infected adults.Role of CD8(+) lymphocytes in control and clearance of measles virus infection of rhesus monkeys.Cross-sectional surveys of measles antibodies in the Jiangsu Province of China from 2008 to 2010: the effect of high coverage with two doses of measles vaccine among childrenAcute measles encephalitis in partially vaccinated adultsAttenuated Salmonella enterica serovar Typhi and Shigella flexneri 2a strains mucosally deliver DNA vaccines encoding measles virus hemagglutinin, inducing specific immune responses and protection in cotton rats.Biological feasibility of measles eradicationA large observational study to concurrently assess persistence of measles specific B-cell and T-cell immunity in individuals following two doses of MMR vaccine
P2860
Q24650526-48B2B5F4-4D68-4BB0-B049-976C3BD79F3AQ24658311-2E261518-0276-46F8-8A1A-0D2D410554BFQ26700081-C2FCB099-CA6D-4257-A3F2-562860DBB3BEQ26829865-9896DCEB-1313-4A48-9FF0-340D1E1AA906Q27014663-0A997C06-D7D5-4554-9DDD-4807E3531ECDQ27487961-B3547A72-12E9-4AC0-ACB8-BD9F5B378C37Q28074714-7575B3A1-E230-4F5A-9FF6-5A026B71CA67Q28749979-AAD89A49-8E12-4700-A0CC-37B42DAD0C18Q28752489-05017C62-96C1-434F-BA41-387A983461ADQ28972559-F7EF5BA0-A929-4B45-A371-23875C53F7C2Q30431941-95605738-4DE2-4986-9736-7E9B2F712228Q30496489-FE998D71-2285-4B4E-9589-AEF143CC0D7FQ31107510-41D795B5-D73C-4C37-AD59-90F3602C7CE6Q33659393-BCFB4707-37DF-42E8-B269-A03E1EC77E70Q33694226-AA41899E-081E-420F-8EE1-0A73270452C7Q33705199-07DC5C89-DEEE-4E40-899A-12FF7A954675Q33769306-7B8622C6-041B-4750-9A83-F21A2C4835EDQ33804540-C19E8F10-954D-43C2-9767-F022ADEE4481Q33808578-92B2DDF6-20AE-4B4C-8839-9277535C2F4EQ33820448-78132F53-14A9-47C4-BB37-33CFDB3EED8DQ33848343-2001364F-F926-4990-B705-5E9C079FBABFQ33908929-5D33473D-59EA-45E6-87C3-50FA74B42798Q33920185-6CABE59A-D535-479C-ACDF-BE5D8DCDBF23Q33930445-E9F327D2-5F2A-4B69-8BC6-E2F1CA0F5DDBQ34124652-AE6E1CA4-99B0-4664-93A8-E72990DAACB6Q34161077-6302C5E6-B190-445C-9073-5460C418F7D5Q34169393-298F4F75-2B6D-4656-B233-90429E63019AQ34343918-5D5B49FD-7138-438C-8317-8342633849E6Q34384582-0C1FFBEB-2DFB-4A7F-82C5-4E7D52F5553CQ34398563-7D89D917-23EF-492A-9312-22F63D81AFF5Q34418405-1919CF44-6C9B-4F3B-A971-93A2FC0F9C57Q34453281-DCC2F684-7495-4616-812C-A00DA4F015CEQ34730474-9E2FE9F6-529A-40E4-9D74-6CBD74D733A2Q34775950-66B5FE25-4698-4CC7-AC69-008220531476Q34781957-6E414792-0216-4AE4-9668-2C3B69CB8AECQ34794244-49A3E1FF-35B0-4ABD-BA5F-76A8E23D9B33Q34964318-BAF3F72C-8311-4FD6-9A1D-1293FC7DF374Q34976024-2138B69F-2CD2-44D8-87DE-D8632082E6D8Q35038217-BD1B21A6-3F09-4DFA-89BD-C66909BF1041Q35051541-28B5EB6F-C8FE-4A33-933D-303585D5B53F
P2860
description
1990 nî lūn-bûn
@nan
1990 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1990 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
name
Measles antibody: reevaluation of protective titers.
@ast
Measles antibody: reevaluation of protective titers.
@en
Measles antibody: reevaluation of protective titers.
@nl
type
label
Measles antibody: reevaluation of protective titers.
@ast
Measles antibody: reevaluation of protective titers.
@en
Measles antibody: reevaluation of protective titers.
@nl
prefLabel
Measles antibody: reevaluation of protective titers.
@ast
Measles antibody: reevaluation of protective titers.
@en
Measles antibody: reevaluation of protective titers.
@nl
P2093
P356
P1476
Measles antibody: reevaluation of protective titers.
@en
P2093
Albrecht P
Markowitz LE
Mofenson LM
Preblud SR
Stewart JA
P304
P356
10.1093/INFDIS/162.5.1036
P407
P577
1990-11-01T00:00:00Z